These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 82767)

  • 41. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
    Sprague PW; Heikes JE; Harris DN; Greenberg R
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():337-43. PubMed ID: 6303073
    [No Abstract]   [Full Text] [Related]  

  • 42. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB; Patscheke H
    Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa.
    Whittle BJ; Kauffman GL; Moncada S
    Nature; 1981 Jul; 292(5822):472-4. PubMed ID: 7195986
    [No Abstract]   [Full Text] [Related]  

  • 46. Synergism between a phosphodiesterase inhibitor and modulators of thromboxane formation on thrombin-induced sudden death in rabbits.
    Smith EF; Olson RW
    Prog Clin Biol Res; 1987; 242():241-6. PubMed ID: 3671385
    [No Abstract]   [Full Text] [Related]  

  • 47. Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases.
    Mesitskaya DF; Syrkin AL; Aksenova MG; Zhang Y; Zamyatnin AA; Kopylov PY
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):81-87. PubMed ID: 30039765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of allitridi on platelet aggregation, a preliminary study.
    Yue ZS; Sun YL; Liu XF; Liao JZ; Yao SZ; Li YL; Chen XY; Fang LG
    J Tradit Chin Med; 1984 Mar; 4(1):29-32. PubMed ID: 6433112
    [No Abstract]   [Full Text] [Related]  

  • 49. Thromboxane A2 synthetase inhibitors with histamine H1-blocking activity: synthesis and evaluation of a new series of indole derivatives.
    Kamiya S; Matsui H; Shirahase H; Nakamura S; Wada K; Kanda M; Shimaji H; Kakeya N
    Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1692-5. PubMed ID: 8536342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combining antiplatelet agents: potentiation between aspirin and dipyridamole.
    Gresele P; Armout J; Deckmyn H; Vermylen J
    Lancet; 1985 Apr; 1(8434):937-8. PubMed ID: 2858787
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effects of a compound prescription of blood activator and tetramethylpyrazine on the biosynthesis of thromboxane A2].
    Wu YS; Chen KJ
    Zhong Xi Yi Jie He Za Zhi; 1985 Mar; 5(3):169-71, 133. PubMed ID: 3157500
    [No Abstract]   [Full Text] [Related]  

  • 52. President lecture. Acute myocardial infarction: current status and prospective view.
    Kawai C
    Jpn Circ J; 1987 Jan; 51(1):5-14. PubMed ID: 3295319
    [No Abstract]   [Full Text] [Related]  

  • 53. Thromboxane synthase inhibition in patients with atherosclerotic heart disease.
    Knudsen JB; Juhl A; Gormsen J
    Lancet; 1981 Jul; 2(8239):198. PubMed ID: 6114260
    [No Abstract]   [Full Text] [Related]  

  • 54. Dipyridamole and platelet function.
    Best LC; Martin TJ; McGuire MB; Preston FE; Russell RG; Segal DS
    Lancet; 1978 Oct; 2(8094):846. PubMed ID: 81402
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacological analysis of factors influencing platelet aggregation in stenosed coronary arteries of dogs.
    Aiken JW
    Ann N Y Acad Sci; 1985; 454():131-4. PubMed ID: 2866748
    [No Abstract]   [Full Text] [Related]  

  • 56. Circulating prostacyclin.
    Lancet; 1978 Jul; 2(8079):21-2. PubMed ID: 78214
    [No Abstract]   [Full Text] [Related]  

  • 57. Prostacyclin: homeostatic regulator or biological curiosity?
    Moncada S; Vane JR
    Clin Sci (Lond); 1981 Oct; 61(4):369-72. PubMed ID: 6269790
    [No Abstract]   [Full Text] [Related]  

  • 58. Increased dipyridamole plasma concentrations associated with salicylate administration. Relationship to effects on platelet aggregation in vivo.
    Buchanan MR; Rosenfeld J; Gent M; Lawrence W; Hirsh J
    Thromb Res; 1979; 15(5-6):813-20. PubMed ID: 494180
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole.
    Gurewich V; Lipinski B
    Thromb Res; 1976 Aug; 9(2):101-8. PubMed ID: 968808
    [No Abstract]   [Full Text] [Related]  

  • 60. Inhibitors of the arachidonate cascade from Allium chinense and their effect on in vitro platelet aggregation.
    Goda Y; Shibuya M; Sankawa U
    Chem Pharm Bull (Tokyo); 1987 Jul; 35(7):2668-74. PubMed ID: 3677224
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.